Two diabetes drugs better than one? new trial aims to find out
NCT ID NCT06613854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether starting two diabetes drugs early—metformin plus either oral semaglutide or empagliflozin—controls blood sugar better than metformin alone in adults recently diagnosed with type 2 diabetes. About 90 participants will take the combination or just metformin for 26 weeks. Researchers will measure blood sugar levels, weight, and other health markers to see if the combo approach is safer and more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
metformin with either oral semaglutide (Rybelsus) or empagliflozin (Jardiance)
What this could lead to
If successful, this could show that starting two diabetes drugs early helps control blood sugar better than metformin alone, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 90 participants, so results may not apply to everyone. The study is short (26 weeks), so long-term benefits or risks are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Medical Centre Ljubljana, Diabetes Outpatient Clinic
RECRUITINGLjubljana, 1000, Slovenia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact